AR024732A1 - METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS. - Google Patents
METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS.Info
- Publication number
- AR024732A1 AR024732A1 ARP000103604A ARP000103604A AR024732A1 AR 024732 A1 AR024732 A1 AR 024732A1 AR P000103604 A ARP000103604 A AR P000103604A AR P000103604 A ARP000103604 A AR P000103604A AR 024732 A1 AR024732 A1 AR 024732A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- pain
- treatment
- cycloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
Abstract
Un método para tratar el dolor cronico que comprende administrar a un sujeto que necesita tal tratamiento una composicion que comprende un inhibidor MEK.Un método para tratar el dolor cronico que comprende administrar a un sujeto que necesita tal tratamiento una composicion que comprende un inhibidor MEKseleccionado de un compuesto que se define mediante la formula 1, R1 es hidrogeno, hidroxi, alquilo C1-8, alcoxi C1-8, halo, trifluorometilo, o CN; R2 eshidrogeno; R3, R4 y R5 son independientemente hidrogeno, hidroxi, halo, trifluorometilo, alquilo C1-8, alcoxi C1-8, nitro, CN, o (O o NH)m-(CH2)n-R9, donde R9es hidrogeno, hidroxi, CO2H, o NR10R11; n es 0-4; m es 0-4; R10 y R11 son independientemente hidrogeno o alquilo C1-8, o tomados juntos con el nitrogeno alcual están unidos pueden completar un anillo cíclico de 3 a 10 miembros que opcionalmente contienen uno, dos o tres heteroátomos seleccioandos de O, S, NH oN-C1-8 alquilo; R6 es hidrogeno, alquilo C1-8, alquilo de O=C-C1-8, arilo, aralquilo o cicloalquilo C3-10; R7 es hidrogeno, alquilo C1-8, alquenilo C2-8,alquinilo C2-8, cicloalquilo que opcionalmente contiene un heteroátomo seleccionado de O, S, o NR9; y donde cualquiera de los grupos alquilo, alquenilo, yalquinilo que anteceden pueden ser no sustituidos o sustituidos por cicloalquilo (o cicloalquilo que opcionalmente contiene un heteroátomo seleccionado de O, S, o NR9), arilo, ariloxi, heteroarilo, o heteroariloxi; o R6 y R7 tomados juntos con el N-O al que están unidos pueden completar un anillo cíclico de 5 a 10miembros, que opcionalmente contienen uno, dos o tres heteroátomos adicionales seleccionado de O, S, o NR10R11. Util en el campo del tratamiento del dolorcronico utilizando inhibidores de MEK. El dolorcronico incluye el dolor neuropático y el dolor por inflamacion cronica.A method for treating chronic pain that comprises administering to a subject in need of such treatment a composition comprising a MEK inhibitor. A method of treating chronic pain that comprises administering to a subject in need of such treatment a composition comprising a MEK inhibitor selected from a compound defined by formula 1, R 1 is hydrogen, hydroxy, C 1-8 alkyl, C 1-8 alkoxy, halo, trifluoromethyl, or CN; R2 is hydrogen; R3, R4 and R5 are independently hydrogen, hydroxy, halo, trifluoromethyl, C1-8 alkyl, C1-8 alkoxy, nitro, CN, or (O or NH) m- (CH2) n-R9, where R9 is hydrogen, hydroxy, CO2H, or NR10R11; n is 0-4; m is 0-4; R10 and R11 are independently hydrogen or C1-8 alkyl, or taken together with the alkaline nitrogen they are attached can complete a cyclic ring of 3 to 10 members that optionally contain one, two or three heteroatoms selected from O, S, NH or N-C1 -8 alkyl; R6 is hydrogen, C1-8 alkyl, O = C-C1-8 alkyl, aryl, aralkyl or C3-10 cycloalkyl; R7 is hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, cycloalkyl which optionally contains a heteroatom selected from O, S, or NR9; and wherein any of the foregoing alkyl, alkenyl, and alkynyl groups may be unsubstituted or substituted by cycloalkyl (or cycloalkyl that optionally contains a heteroatom selected from O, S, or NR9), aryl, aryloxy, heteroaryl, or heteroaryloxy; or R6 and R7 taken together with the N-O to which they are attached can complete a cyclic ring of 5 to 10 members, which optionally contain one, two or three additional heteroatoms selected from O, S, or NR10R11. Useful in the field of pain pain treatment using MEK inhibitors. Chronic pain includes neuropathic pain and chronic inflammation pain.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14429299P | 1999-07-16 | 1999-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024732A1 true AR024732A1 (en) | 2002-10-23 |
Family
ID=22507940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000103604A AR024732A1 (en) | 1999-07-16 | 2000-07-13 | METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1202726A2 (en) |
| JP (1) | JP2003504400A (en) |
| KR (1) | KR20020012315A (en) |
| CN (1) | CN1373660A (en) |
| AR (1) | AR024732A1 (en) |
| AU (1) | AU5786000A (en) |
| CA (1) | CA2374052A1 (en) |
| CO (1) | CO5300398A1 (en) |
| HU (1) | HUP0202623A3 (en) |
| IL (1) | IL147619A0 (en) |
| NZ (1) | NZ515567A (en) |
| PE (1) | PE20010545A1 (en) |
| PL (1) | PL352684A1 (en) |
| TR (1) | TR200200082T2 (en) |
| WO (1) | WO2001005392A2 (en) |
| ZA (1) | ZA200109907B (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001273498B2 (en) | 2000-07-19 | 2006-08-24 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| SG148857A1 (en) | 2002-03-13 | 2009-01-29 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
| CA2532067C (en) | 2003-07-24 | 2010-12-21 | Stephen Douglas Barrett | N-methyle-substituted benzamidazoles |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| AU2004279721A1 (en) * | 2003-10-08 | 2005-04-21 | Teijin Pharma Limited | Process for producing aminopyrrolidine derivative and intermediate compound |
| EP1682495A1 (en) | 2003-10-21 | 2006-07-26 | Warner-Lambert Company LLC | Polymorphic form of n- (r)-2,3-dihydroxy-propoxy -3,4-d ifluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| AU2004293019B2 (en) | 2003-11-19 | 2010-10-28 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
| KR101223914B1 (en) | 2003-11-21 | 2013-01-18 | 어레이 바이오파마 인크. | Akt protein kinase inhibitors |
| MY144232A (en) * | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| TWI441637B (en) | 2005-05-18 | 2014-06-21 | Array Biopharma Inc | Heterocyclic inhibitors of mek and methods of use thereof |
| EA019983B1 (en) | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Mek inhibitors and methods of using same |
| MY147628A (en) | 2006-07-06 | 2012-12-31 | Array Biopharma Inc | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| WO2008006039A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
| DE602007011628D1 (en) | 2006-07-06 | 2011-02-10 | Array Biopharma Inc | DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CA2671982C (en) | 2006-12-14 | 2016-01-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| CA2692506C (en) | 2007-07-05 | 2015-11-24 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| CN103396409B (en) | 2007-07-05 | 2015-03-11 | 阵列生物制药公司 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2009037707A2 (en) * | 2007-09-20 | 2009-03-26 | Ramot At Tel Aviv University Ltd. | N-phenyl anthranilic acid derivatives and uses thereof |
| JP5511680B2 (en) | 2007-12-19 | 2014-06-04 | キャンサー・リサーチ・テクノロジー・リミテッド | Pyrido [2,3-B] pyrazine-8-substituted compounds and uses thereof |
| CA2711699A1 (en) | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| EP2240455B1 (en) | 2008-01-09 | 2012-12-26 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
| ES2399384T3 (en) | 2008-11-10 | 2013-04-01 | Bayer Schering Pharma Ag | Sulfonamido substituted phenoxybenzamides |
| US8962606B2 (en) | 2009-10-21 | 2015-02-24 | Bayer Intellectual Property Gmbh | Substituted benzosulphonamides |
| CA2777430A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
| EP2491014A1 (en) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
| PL2531502T3 (en) | 2010-02-01 | 2014-08-29 | Cancer Research Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
| SG194048A1 (en) | 2011-04-01 | 2013-11-29 | Genentech Inc | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use |
| CN103841976A (en) | 2011-04-01 | 2014-06-04 | 基因泰克公司 | Combinations of AKT AND MEK inhibitor compounds, and methods of use |
| SI2909188T1 (en) | 2012-10-12 | 2018-07-31 | Exelixis, Inc. | Novel process for making compounds for use in the treatment of cancer |
| CA2923835C (en) * | 2013-09-11 | 2022-11-29 | The Administrators Of The Tulane Educational Fund | Novel anthranilic amides and the use thereof |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA3001879A1 (en) * | 2015-10-27 | 2017-05-04 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors for the treatment of diabetic peripheral neuropathy |
| DK3697405T3 (en) * | 2017-10-17 | 2021-08-23 | Atriva Therapeutics Gmbh | NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS |
| CN114008013A (en) * | 2019-06-28 | 2022-02-01 | 哥本哈根大学 | Treatment of CNS disorders with sleep disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251943B1 (en) * | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
| ES2274572T3 (en) * | 1997-07-01 | 2007-05-16 | Warner-Lambert Company Llc | ACID DERIVATIVES 2- (4-BROMO- OR 4-IODO-PHENYLAMINE) BENZOIC AND ITS USE AS A MEK INHIBITOR. |
| WO1999001426A1 (en) * | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| JP2002532415A (en) * | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Treatment of arthritis with MEK inhibitors |
-
2000
- 2000-07-05 HU HU0202623A patent/HUP0202623A3/en unknown
- 2000-07-05 IL IL14761900A patent/IL147619A0/en unknown
- 2000-07-05 CA CA002374052A patent/CA2374052A1/en not_active Abandoned
- 2000-07-05 CN CN00809801A patent/CN1373660A/en active Pending
- 2000-07-05 NZ NZ515567A patent/NZ515567A/en unknown
- 2000-07-05 TR TR2002/00082T patent/TR200200082T2/en unknown
- 2000-07-05 AU AU57860/00A patent/AU5786000A/en not_active Abandoned
- 2000-07-05 KR KR1020027000609A patent/KR20020012315A/en not_active Application Discontinuation
- 2000-07-05 WO PCT/US2000/018347 patent/WO2001005392A2/en not_active Application Discontinuation
- 2000-07-05 PL PL00352684A patent/PL352684A1/en not_active Application Discontinuation
- 2000-07-05 EP EP00943383A patent/EP1202726A2/en not_active Withdrawn
- 2000-07-05 JP JP2001510449A patent/JP2003504400A/en active Pending
- 2000-07-13 AR ARP000103604A patent/AR024732A1/en unknown
- 2000-07-14 CO CO00053304A patent/CO5300398A1/en not_active Application Discontinuation
- 2000-07-14 PE PE2000000705A patent/PE20010545A1/en not_active Application Discontinuation
-
2001
- 2001-11-30 ZA ZA200109907A patent/ZA200109907B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020012315A (en) | 2002-02-15 |
| CN1373660A (en) | 2002-10-09 |
| HUP0202623A3 (en) | 2003-03-28 |
| AU5786000A (en) | 2001-02-05 |
| EP1202726A2 (en) | 2002-05-08 |
| PE20010545A1 (en) | 2001-06-04 |
| PL352684A1 (en) | 2003-09-08 |
| WO2001005392A2 (en) | 2001-01-25 |
| JP2003504400A (en) | 2003-02-04 |
| CO5300398A1 (en) | 2003-07-31 |
| CA2374052A1 (en) | 2001-01-25 |
| NZ515567A (en) | 2004-03-26 |
| ZA200109907B (en) | 2003-02-28 |
| TR200200082T2 (en) | 2002-04-22 |
| WO2001005392A3 (en) | 2001-07-19 |
| IL147619A0 (en) | 2002-08-14 |
| HUP0202623A2 (en) | 2002-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024732A1 (en) | METHOD FOR THE TREATMENT OF CHRONIC PAIN THROUGH THE USE OF MEK INHIBITORS. | |
| AR016762A1 (en) | 4-BROMO OR 4-IODINE PHENYLAMINE BENZOHIDROXAMIC ACID COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USE OF THE SAME | |
| HRP20031098B1 (en) | Beta-amino tetrahydroimidazo (1,2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | |
| ATE323717T1 (en) | PIPERAZINE-4-PHENYL DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND MDM2 | |
| DK0880508T3 (en) | Quinazoline derivatives as VEGF inhibitors | |
| HUP0402376A2 (en) | Imidazole-4-carboxamide derivatives, their preparation and pharmaceutical compositions suitable for treatment of obesity containing them | |
| TW200510353A (en) | Alpha substituted carboxylic acids as PPAR modulators | |
| RU2011106374A (en) | CYCLIC INHIBITORS 11BETA-HYDROXYSTEROID-DEHYDROGENASE 1 | |
| PT892793E (en) | DERIVATIVES 2-CYANOIMINOIMIDAZOLE PDE IV INHIBITORS | |
| BR9307580A (en) | Process compounds for the preparation of the same pharmaceutical compositions use of a compound and process for the treatment of a mammal that includes humans | |
| DE59410181D1 (en) | NEW THIAZOLIDE INDIONS AND MEDICINAL PRODUCTS CONTAINING THEM | |
| TR199701219T1 (en) | Benzimidazole compounds, these compounds are Spanish compounds. | |
| HRP20090264T1 (en) | Phenyl-piperazin methanone derivatives | |
| DE60316672D1 (en) | POLYCYCLIC COMPOUNDS AS POTENTIAL ALPHA2 ADRENOCEPTOR ANTAGONISTS | |
| SE9701304D0 (en) | Compounds | |
| ES2083972T3 (en) | ARYLALKYL-AMINES AND -AMIDES WITH ANTICONVULSIVE AND NEUROPROTECTORAL PROPERTIES. | |
| DE69910083D1 (en) | CATECHOLHYDRAZONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| ES2262504T3 (en) | DERIVATIVES OF THE PYROGLUTAMIC ACID AND RELATED COMPOUNDS THAT INHIBIT THE ADHESION OF LEUKOCYTES THROUGH THE VLA-4. | |
| DK0787491T3 (en) | Remedy for the prevention and treatment of type I allergic diseases | |
| DK524283A (en) | PROCEDURE FOR NITROSOURE ADDITIVES | |
| FI940568A0 (en) | Oxindole-1- (N- (alkoxycarbonyl)) carboxyamides and 1-N-carboxamido) carboxamides as anti-inflammatory agents | |
| CO5031336A1 (en) | FUNGICIDE BLENDS CONTAINING CARBAMATES AND AN AROMATIC DERIVATIVE | |
| AR007937A1 (en) | A COMPOUND DERIVED FROM BENCIMIDAZOLE, A PROCEDURE FOR PREPARING IT, A MEDICATION CONSTITUTED BY SUCH A COMPOUND AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH A COMPOUND | |
| ES408605A1 (en) | 2-Substituted oxazole-4,5-dicarboxamides | |
| SE9702534D0 (en) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |